Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vittorio Rosti

Showing results (11-20 of 156) with videos related to

Pageof 16
Sort By:
Current Pharmaceutical Biotechnology|August 10, 2018
Manipulating Intracellular Ca2+ Signals to Stimulate Therapeutic Angiogenesis in Cardiovascular DisordersFrancesco Moccia, Roberto Berra-Romani, Vittorio Rosti
Blood Advances|November 13, 2023
JAK2V617F and ischemic stroke: CHIP or CMD-NBV?Giovanni Barosi, Vittorio Rosti, Robert Peter Gale
Leukemia|March 4, 2023
Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectivesGiovanni Barosi, Vittorio Rosti, Robert Peter Gale
Ejhaem|April 10, 2026
Are Myeloproliferative Neoplasms-Unclassifiable Really Unclassifiable?Giovanni Barosi, Vittorio Rosti, Robert P Gale
Oncotargets and Therapy|June 10, 2015
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisGiovanni Barosi, Vittorio Rosti, Robert Peter Gale
European Journal of Cancer (Oxford, England : 1990)|December 29, 2009
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspectiveAlberto Zambelli, Matteo Della Porta, Vittorio Rosti
Cancers|November 13, 2021
New Markers of Disease Progression in MyelofibrosisRita Campanelli, Margherita Massa, Vittorio Rosti, et al.
Haematologica|May 21, 2026
Response to Comment on: "Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm."Giovanni Barosi, Vittorio Rosti, Luca Malcovati, et al.
Leukemia|January 22, 2026
Prognostic value of anemia plus thrombocytopenia in primary myelofibrosisGiovanni Barosi, Annalisa De Silvestri, Robert Peter Gale, et al.
Experimental Hematology|December 17, 2013
CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosisRita Campanelli, Vittorio Rosti, Gabriela Fois, et al.
Pageof 16

Showing results (11-20 of 156) with videos related to

Sort By:
Pageof 16
Current Pharmaceutical Biotechnology|August 10, 2018
Manipulating Intracellular Ca2+ Signals to Stimulate Therapeutic Angiogenesis in Cardiovascular DisordersFrancesco Moccia, Roberto Berra-Romani, Vittorio Rosti
Blood Advances|November 13, 2023
JAK2V617F and ischemic stroke: CHIP or CMD-NBV?Giovanni Barosi, Vittorio Rosti, Robert Peter Gale
Leukemia|March 4, 2023
Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectivesGiovanni Barosi, Vittorio Rosti, Robert Peter Gale
Ejhaem|April 10, 2026
Are Myeloproliferative Neoplasms-Unclassifiable Really Unclassifiable?Giovanni Barosi, Vittorio Rosti, Robert P Gale
Oncotargets and Therapy|June 10, 2015
Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosisGiovanni Barosi, Vittorio Rosti, Robert Peter Gale
European Journal of Cancer (Oxford, England : 1990)|December 29, 2009
From cancer patients to cancer survivors: the issue of Cardioncology--a biological perspectiveAlberto Zambelli, Matteo Della Porta, Vittorio Rosti
Cancers|November 13, 2021
New Markers of Disease Progression in MyelofibrosisRita Campanelli, Margherita Massa, Vittorio Rosti, et al.
Haematologica|May 21, 2026
Response to Comment on: "Clonal megakaryocyte dysplasia with normal blood values: a covert, thrombosis-prone, early myeloproliferative neoplasm."Giovanni Barosi, Vittorio Rosti, Luca Malcovati, et al.
Leukemia|January 22, 2026
Prognostic value of anemia plus thrombocytopenia in primary myelofibrosisGiovanni Barosi, Annalisa De Silvestri, Robert Peter Gale, et al.
Experimental Hematology|December 17, 2013
CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosisRita Campanelli, Vittorio Rosti, Gabriela Fois, et al.
Pageof 16